Several clinical trials have indicated cardiovascular beneficial effects of SGLT2 inhibitors by lowering mortality from cardiovascular causes and hospitalization for heart failure in type 2 diabetic mellitus patients (T2DM) with established cardiovascular diseases [21–23] and these effects appeared to be independent of glycemic control [24, 25]. The gene discussed is SLC5A2; the disease is cardiovascular disorder.